Plasma cell-free DNA methylomes for hepatocellular carcinoma detection and monitoring after liver resection or transplantation

Kui Chen,Zhihao Li,Bianca O. Kirsh,Ping Luo,Stephanie Pedersen,Roxana C. Bucur,Nadia A. Rukavina,Jeffrey P. Bruce,Arnavaz Danesh,Mazdak Riverin,Sandra E. Fischer,Mamatha Bhat,Nazia Selzner,Sonya A. MacParland,Carol-Anne Moulton,Steven Gallinger,Ian D. McGilvray,Mark S. Cattral,Markus Selzner,Trevor W. Reichman,Chaya Shwaartz,Blayne A. Sayed,Sean P. Cleary,Gonzalo Sapisochin,Anand Ghanekar,Trevor J. Pugh

DOI: https://doi.org/10.1101/2024.10.01.24314116

2024-10-02

Abstract:Hepatocellular carcinoma (HCC) is a highly lethal malignancy with frequent recurrence after curative-intent surgery. Current detection and monitoring methods rely heavily on imaging, and genomic strategies are limited by access to tumor tissue and the challenges of mutational heterogeneity. Therefore, a cost-effective noninvasive approach with sufficient sensitivity, specificity, and high accuracy is needed to enhance HCC management. In this study, we evaluated the clinical potential of cfMeDIP-seq for HCC detection and postoperative monitoring. A total of 236 cfDNA samples were collected at surgery (b-HCC, n=89) and during follow-up (f-HCC, n=112) from 89 HCC patients undergoing liver transplantation (n=57) or resection (n=32), along with 35 healthy controls (CTL). cfMeDIP-seq was performed, followed by machine learning to develop an HCC-specific classifier in a discovery cohort (52 b-HCC vs. 35 CTL), which was subsequently tested in a validation cohort of 37 patients. An HCC methylation score (HMS) was assigned to reflect the probability of a sample containing HCC-derived cfDNA, and relationships between HMS and clinical variables were assessed. The classifier identified HCC with 97% sensitivity and 99% specificity in the discovery cohort and 97% accuracy in the validation cohort. Baseline HMS >0.9 was associated with higher recurrence risk (HR 3.43, 95% CI 1.30-9.06, p=0.013), and HMS decreased by 3-44% (median 17%) within 13 weeks post-surgery. HMS trajectories diverged for recurrent and non-recurrent patients, with an increase in HMS indicating clinical recurrence, and the HMS was independent of other clinicopathologic variables. These findings demonstrate that tumor-agnostic cfDNA methylomes can accurately detect HCC and predict recurrence after liver resection or transplantation, suggesting that this approach may have important implications for HCC diagnosis, treatment, and monitoring.